Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Blood Cancer Journal
|
March 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)
Juying Wei, Qingqing Cai, Liling Zhang, et al.
American Journal of Hematology
|
January 23, 2023
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study
Wei Xu, Keshu Zhou, Tingyu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study
Huiqiang Huang, Rong Tao, Siguo Hao, et al.
Bone Marrow Transplantation
|
February 27, 2019
Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation
Baolin Tang, Xiaoyu Zhu, Changcheng Zheng, et al.
Frontiers in Oncology
|
July 25, 2022
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)
Yuqin Song, Keshu Zhou, Chuan Jin, et al.
American Journal of Hematology
|
August 30, 2023
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
Lijuan Deng, Zhiming Li, Huilai Zhang, et al.
The Lancet. Oncology
|
December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Yuqin Song, Luis Malpica, Qingqing Cai, et al.
Frontiers in Oncology
|
November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
Weiping Liu, Donglu Zhao, Ting Liu, et al.
Signal Transduction and Targeted Therapy
|
July 5, 2026
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial
Fei Li, Keshu Zhou, Wei Xu, et al.
Journal of Hematology & Oncology
|
March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi, Bo Jia, Wei Xu, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Blood Cancer Journal
|
March 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)
Juying Wei, Qingqing Cai, Liling Zhang, et al.
American Journal of Hematology
|
January 23, 2023
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study
Wei Xu, Keshu Zhou, Tingyu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study
Huiqiang Huang, Rong Tao, Siguo Hao, et al.
Bone Marrow Transplantation
|
February 27, 2019
Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation
Baolin Tang, Xiaoyu Zhu, Changcheng Zheng, et al.
Frontiers in Oncology
|
July 25, 2022
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)
Yuqin Song, Keshu Zhou, Chuan Jin, et al.
American Journal of Hematology
|
August 30, 2023
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
Lijuan Deng, Zhiming Li, Huilai Zhang, et al.
The Lancet. Oncology
|
December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Yuqin Song, Luis Malpica, Qingqing Cai, et al.
Frontiers in Oncology
|
November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
Weiping Liu, Donglu Zhao, Ting Liu, et al.
Signal Transduction and Targeted Therapy
|
July 5, 2026
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial
Fei Li, Keshu Zhou, Wei Xu, et al.
Journal of Hematology & Oncology
|
March 17, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi, Bo Jia, Wei Xu, et al.
Page
of 5